Official websites use .gov
A
.gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to
the .gov website. Share sensitive information only on official,
secure websites.
N/A
12.420
Through the support of basic, applied, and advanced biomedical research: (1) to transform health care for Service Members and the American public through innovative and impactful research; (2) to investigate medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical and biological defense, clinical and rehabilitative medicine, blast injury and regenerative medicine; and (3) to fund novel approaches to biomedical research in response to the expressed needs of Congress.
This chart shows obligations for the program by fiscal year. All data for this chart was provided by the
administering agency and sourced from SAM.gov, USASpending.gov, and Treasury.gov.
For more information on each of these data sources, please see the
About the data page.
Funding is supporting a broad range of medical solutions, including: (1) advancement of research in psychological health, sensory systems, pain management, and regenerative medicine, (2) addressing critical gaps in medical training/simulation, infection and wound healing, acute trauma care, operational readiness, radiation health effects, and rehabilitation, (3) development and clinical testing of immunotherapies and vaccines to treat or prevent cancer and infectious diseases, (4) discovery of new treatments for prevalent conditions such as diabetes and autism and for trauma-related conditions such as tissue, orthopaedic, and spinal cord injuries, and (5) development of novel imaging and diagnostic technologies for traumatic injuries, cancer, and Alzheimer’s disease. Funding is supporting a broad range of medical solutions, including: (1) advancement of research in psychological health, sensory systems, pain management, and regenerative medicine, (2) addressing critical gaps in medical training/simulation, infection and wound healing, acute trauma care, operational readiness, radiation health effects, and rehabilitation, (3) development and clinical testing of immunotherapies and vaccines to treat or prevent cancer and infectious diseases, (4) discovery of new treatments for prevalent conditions such as diabetes and autism and for trauma-related conditions such as tissue, orthopaedic, and spinal cord injuries, and (5) development of novel imaging and diagnostic technologies for traumatic injuries, cancer, and Alzheimer’s disease.
Information on past projects funded under this Assistance Listing may be found on the Defense Technical Information Center’s website at: https://dodgrantawards.dtic.mil/grants/#/home. Click on “Advanced Search” then select the “Medical Research & Material Command/Congressionally Directed Medical Research Programs” under “DoD Awarding Agency
The Congressionally Directed Medical Research Programs (CDMRP) is a global funding organization that fosters novel approaches to biomedical research in response to the expressed needs of its stakeholders–the American public, the military, and Congress. CDMRP originated in 1992 when Congress first appropriated funds to the Department of Defense (DOD), specifically for breast cancer research. Since that time, Congress has added additional research programs and topics. CDMRP now manages individual research programs focused on military medical research, cancer research, and other disease-, disorder-, and injury-specific research. All the programs managed by CDMRP share the common goal of advancing paradigm-shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. CDMRP strives to transform healthcare for Service members and the American public by funding innovative and impactful research. CDMRP oversees the investment of congressionally directed dollars to fund groundbreaking, high-impact, high-risk, high-reward, meritorious research that targets critical research gaps. CDMRP also provides management support of intramural and extramural military medical research.
CDMRP is located under the US Army Futures Command and within US Army Medical Research and Development Command (USAMRDC). Since it first originated in fiscal year 1992 (FY92), CDMRP has been responsible for managing more than $15.94 billion (B) in funding targeted for congressionally directed research areas/topics.
Since the first program appropriation in 1992, Congressionally-Directed Medical Research Program (CDMRP) funded research has significantly advanced knowledge, technologies, and products that are saving and improving lives: • U.S. Food and Drug Administration (FDA)-approved drugs and therapeutic strategies • Diagnostic and prognostic biomarkers/tests • Novel approaches to prevention and treatment • Imaging technologies for clinical use • New standards of care and clinical practice • Biorepositories with clinical samples and data Additional research accomplishment highlights for each CDMRP program can be found at: https://cdmrp.army.mil/highlights/default Highlights are available in individual program materials as well as the CDMRP Annual Report published each year: https://cdmrp.army.mil/pubs/annreports/annual_reports
Since the first program appropriation in 1992, research funded by the Congressional Directed Medical Research Program (CDMRP) within the Defense Health Program (DHP), significantly advanced knowledge, technologies, and products that are saving and improving lives. Examples include: • FDA-approved drugs and therapeutic strategies • Diagnostic and prognostic biomarkers/tests • Novel approaches to prevention and treatment • Imaging technologies for clinical use • New standards of care and clinical practice • Biorepositories with clinical samples and data
In 2024, the Congressionally Directed Medical Research Program (CDMRP, a major component of the DHP) managed administered 34 FY2024 Congressional Special Interest programs. The CDMRP also provided program and award management support to other core Department of Defense (DOD) medical research programs. The CDRMP invests in groundbreaking research across the full spectrum of research and development, including basic, translational, and clinical research. By strategically funding high-risk, high-reward research projects that other agencies may not be willing to fund, the CDMRP addresses critical research gaps. CDMRP-funded research benefits not only military members, military retirees, and family members, but the civilian population as well. The CDMRP underwent a comprehensive review by the Comptroller General, as directed in the FY21 Defense Appropriations Act (HR 133). The GAO favorably assessed the CDMRP and provided entirely positive findings, listing no deficiencies and providing no recommendations for change.
Single Audit Applies (2 CFR Part 200 Subpart F):
For additional information on single audit requirements for this program, review the current Compliance Supplement.
OMB is working with the U.S. Government Accountability Office (GAO) and agency offices of inspectors general to include links to relevant oversight reports. This section will be updated once this information is made available.
